184 related articles for article (PubMed ID: 36797358)
21. Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients.
Kato MK; Yoshida H; Tanase Y; Uno M; Ishikawa M; Kato T
Pathol Oncol Res; 2021; 27():598550. PubMed ID: 34257552
[No Abstract] [Full Text] [Related]
22. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
[TBL] [Abstract][Full Text] [Related]
23. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.
Loukovaara M; Pasanen A; Bützow R
Cancer Med; 2021 Feb; 10(3):1034-1042. PubMed ID: 33449452
[TBL] [Abstract][Full Text] [Related]
24. Biomarker-driven therapy in endometrial cancer.
Karpel H; Slomovitz B; Coleman RL; Pothuri B
Int J Gynecol Cancer; 2023 Mar; 33(3):343-350. PubMed ID: 36878569
[TBL] [Abstract][Full Text] [Related]
25. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
Leskela S; Romero I; Rosa-Rosa JM; Caniego-Casas T; Cristobal E; Pérez-Mies B; Gutierrez-Pecharroman A; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; Andrada E; Montes S; Pastor F; Gomez MC; López-Guerrero JA; Poveda A; Palacios J
Am J Surg Pathol; 2020 Jul; 44(7):982-990. PubMed ID: 32384322
[TBL] [Abstract][Full Text] [Related]
26. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
[TBL] [Abstract][Full Text] [Related]
27. FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes.
Sengal AT; Patch AM; Snell CE; Smith DS; Leung SCY; Talhouk A; Williams ED; McAlpine JN; Pollock PM
Clin Cancer Res; 2020 Sep; 26(17):4569-4580. PubMed ID: 32414751
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
[TBL] [Abstract][Full Text] [Related]
29. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
30. Endometrial Cancer: Transitioning from Histology to Genomics.
Mitric C; Bernardini MQ
Curr Oncol; 2022 Jan; 29(2):741-757. PubMed ID: 35200562
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups.
Rau TT; Bettschen E; Büchi C; Christe L; Rohner A; Müller MD; Carlson JW; Imboden S; Zlobec I
Mod Pathol; 2021 Jan; 34(1):222-232. PubMed ID: 32728223
[TBL] [Abstract][Full Text] [Related]
32. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.
Krämer P; Talhouk A; Brett MA; Chiu DS; Cairns ES; Scheunhage DA; Hammond RFL; Farnell D; Nazeran TM; Grube M; Xia Z; Senz J; Leung S; Feil L; Pasternak J; Dixon K; Hartkopf A; Krämer B; Brucker S; Heitz F; du Bois A; Harter P; Kommoss FKF; Sinn HP; Heublein S; Kommoss F; Vollert HW; Manchanda R; de Kroon CD; Nijman HW; de Bruyn M; Thompson EF; Bashashati A; McAlpine JN; Singh N; Tinker AV; Staebler A; Bosse T; Kommoss S; Köbel M; Anglesio MS
Clin Cancer Res; 2020 Oct; 26(20):5400-5410. PubMed ID: 32737030
[TBL] [Abstract][Full Text] [Related]
33. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations.
Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF
Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482
[TBL] [Abstract][Full Text] [Related]
34. Molecular testing for endometrial cancer: An SGO clinical practice statement.
Walsh CS; Hacker KE; Secord AA; DeLair DF; McCourt C; Urban R
Gynecol Oncol; 2023 Jan; 168():48-55. PubMed ID: 36399812
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
[TBL] [Abstract][Full Text] [Related]
36. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
[TBL] [Abstract][Full Text] [Related]
37. Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.
Santoro A; Angelico G; Travaglino A; Raffone A; Arciuolo D; D'Alessandris N; Inzani F; Zannoni GF
Gynecol Oncol; 2021 May; 161(2):629-635. PubMed ID: 33712277
[TBL] [Abstract][Full Text] [Related]
38. Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer.
Swift BE; Gien LT
Curr Treat Options Oncol; 2022 Aug; 23(8):1121-1134. PubMed ID: 35793055
[TBL] [Abstract][Full Text] [Related]
39. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
